Nevertheless, it has been reported that somatic genomic alterations in malignant HCTs are represented by Mucosal Vascular Address in Cell Adhesion Molecule 1 (MADCAM-1) (20%), EIF1AX (11%), DAXX, PT53 (7%) and Neurofibromatosis type 1 (NF1) (7%) mutations, while no BRAF mutations and a lower rate of NRAS (9%) mutation are encountered in comparison to FTC cases [77,78,79] (Table 2). This evidence concerns the gene BRAF and thyroid cancer, nonmedullary, 2.